Incidencen af akutte afstødningsepisoder var væsentligt lavere hos patienter behandlet med basiliximab og tre- stofs - lægemiddel immunosuppressiv behandling.
The incidence of acute rejection episode was substantially lower in patients receiving basiliximab and a triple drug immunosuppressive regimen.